Compare JAGX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | RDHL |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.0M |
| IPO Year | 2014 | 2012 |
| Metric | JAGX | RDHL |
|---|---|---|
| Price | $0.32 | $1.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 476.7K | 39.0K |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | N/A |
| Revenue This Year | $61.58 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.71 |
| 52 Week High | $13.25 | $3.31 |
| Indicator | JAGX | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 70.57 |
| Support Level | N/A | $0.79 |
| Resistance Level | $0.46 | $1.07 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.58 | 86.20 |
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.